Evaluating Patients With Varying Degrees of Renal Function

Renal Impairment Clinical Trial

Official title:

A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00398307
• Other study ID #: TPU-S1111
• Status: Completed
• Phase: Phase 1
• Start date: February 2006
• Est. completion date: September 2010

Study information

• Verified date: September 2021
• Source: Taiho Oncology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula: Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A patient must meet all of the following inclusion criteria to be eligible for

enrollment in this study:

1. Has histologically or cytologically proven advanced solid tumors for which no standard therapy exists.

2. Has provided written informed consent.

3. Is 18 years of age or older.

4. Is able to take medications orally.

5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to = 2 Appendix A,ECOG Performance Status).

6. Has adequate organ function as defined by the following criteria:

1. Transaminases AST (SGOT) and ALT (SGPT) = 2.5 times the upper limit of normal(ULN). If liver function abnormalities are due to underlying malignancy, then AST(SGOT) and ALT (SGPT) may be = 5 times ULN.

2. Total serum bilirubin = 1.5 times ULN.

3. Absolute granulocyte count = 1,500/mm3 (ie, = 1.5 x 109/L by International Units [IU]).

4. Has a platelet count = 100,000/mm3 (IU: = 100 x 109/L).

5. Has a hemoglobin value of = 9.0 g/dL.

7. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3.3.2 Exclusion Criteria Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if

any of the following conditions are observed:

1. Has had treatment with any of the following within the specified time frame prior to

study drug administration:

1. Any investigational agent received either concurrently or within the last 30 days.

2. Previous therapy for malignancy within 21 days, including any chemotherapy, immunotherapy, biologic or hormonal therapy (6 weeks for nitrosoureas or mitomycin(C).

3. Previous radiotherapy within 14 days.

4. Current enrollment in another clinical trial.

2. Has a serious illness or medical condition(s) including, but not limited to, the

following:

1. Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] Class III or IV, Appendix E, NYHA Classification).

2. Known (at the time of entry) gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.

3. Known brain metastasis.

4. Known leptomeningeal metastases.

5. Requires hemodialysis.

6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome(AIDS)-related illness.

7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.

3. Is receiving a concomitant treatment with drugs interacting with S-1. The following

drugs are prohibited because there may be an interaction with S-1:

1. Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1 activity).

2. Allopurinol (may diminish S-1 activity).

3. Phenytoin (S-1 may enhance phenytoin activity).

4. Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and flucytosine activity).

5. Pilocarpine (may inhibit CYP2A6 activity).

4. Has known sensitivity to 5-FU.

5. Is a pregnant or lactating female.

6. Is a patient with reproductive potential who refuses to use an adequate means of contraception

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• S-1/Cisplatin
S-1 administration will be determined by degree of renal impairment as follows: Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD Pharmacokinetic Phase (Part 1): On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning. Treatment will be followed by 1 week of recovery (Days 15 through 21). Extension Phase (Part 2): S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.

Locations

Country	Name	City	State
United States	Cancer Research & Treatment Center/University of New Mexico	Albuquerque	New Mexico
United States	University of Maryland/Greenebaum Cancer Center	Baltimore	Maryland
United States	University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation	Lexington	Kentucky
United States	LAC/USC Medical Center	Los Angeles	California
United States	Yale Cancer Center	New Haven	Connecticut
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	The Institute for Drug Development	San Antonio	Texas
United States	Premiere Oncology	Santa Monica	California
United States	Premiere Oncology of Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Taiho Oncology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To provide specific dosing recommendations for S-1 in patients with renal impairment based on the PK of S-1 and its components after single dose and steady state conditions.		The Pharmacokinetic Phase (Part 1) of the study will last 24 days.
Secondary	Assess Anti-tumor activity, and safety profile of S-1 in patients with impaired renal function		Each cycle of the Extension Phase (Part 2) will be 21 days (14 days of S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1.